

Press Release

Regulated information

DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 27 March 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 19 March to 27 March 2013, it acquired 41,944 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
19 March 2013	4,200	€ 20.5638	€ 20.35	€ 20.63	€ 86,368
20 March 2013	5,000	€ 20.5786	€ 20.43	€ 20.67	€ 102,893
21 March 2013	6,203	€ 20.4085	€ 20.24	€ 20.50	€ 126,594
22 March 2013	10,600	€ 20.2348	€ 20.12	€ 20.47	€ 214,489
25 March 2013	9,766	€ 20.2539	€ 19.98	€ 20.40	€ 197,800
26 March 2013	2,105	€ 20.3818	€ 20.20	€ 20.50	€ 42,904
27 March 2013	4,070	€ 20.4034	€ 20.25	€ 20.49	€ 83,042

In addition, during the period from 19 March to 27 March 2013, Arseus acquired 78,798 treasury shares via various block trades.

Acquisition date	Block	Price	Amount
21 March 2013	10,000	€ 20.4500	€ 204,500
22 March 2013	1,800	€ 20.4200	€ 36,756
22 March 2013	3,164	€ 20.3600	€ 64,419
22 March 2013	1,834	€ 20.3800	€ 37,377
22 March 2013	6,000	€ 20.1000	€ 120,600
26 March 2013	20,000	€ 20.4000	€ 408,000

¹ This press release was sent out by Arseus NV and Arseus BV.

26 March 2013	10,000	€ 20.2600	€ 202,600
27 March 2013	6,000	€ 20.3000	€ 121,800
27 March 2013	20,000	€ 20.4800	€ 409,600

Further, Arseus transferred 14,121 shares on 25 March 2013 at a price of € 20.12 per share as subsequent payment for an acquisition.

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus already held 853,675 treasury shares. As a result of the transactions referred to above, Arseus now holds 960,296 treasury shares, representing 3.07% of the total number of shares outstanding.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

Constantijn van Rietschoten
 Director of Corporate Communications
 +31 88 33 11 222 (Office)
 +31 6 536 91 585 (Mobile)
constantijn.van.rietschoten@arseus.com

Veronique Lefel
 Investor Relations Officer
 +31 88 33 11 213 (Office)
 +31 6 105 77 754 (Mobile)
veronique.lefel@arseus.com

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 29 countries in Europe, North America, South America, Asia, Australia and Africa. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.